Nanomedicine in the treatment of diabetic nephropathy

被引：14

作者：

Desai, Nimeet ^{[1
]}

Koppisetti, HariPriya ^{[1
]}

Pande, Shreya ^{[1
]}

Shukla, Havish ^{[1
]}

Sirsat, Bhagwat ^{[1
]}

Ditani, Aayushi S. ^{[1
]}

Mallick, Pragyan P. ^{[1
]}

Kathar, Umesh ^{[1
]}

Kalia, Kiran ^{[1
]}

Tekade, Rakesh K. ^{[1
]}

机构：

[1] Govt India, Dept Pharmaceut, Minist Chem & Fertilizers,Inst Natl Importance, Natl Inst Pharmaceut Educ & Res Ahmedabad NIPER A, Gandhinagar 382355, Gujarat, India

来源：

FUTURE MEDICINAL CHEMISTRY | 2021年 / 13卷 / 07期

关键词：

diabetic nephropathy; molecular mechanics; nanomedicine; targeted drug delivery; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MOLECULAR-WEIGHT CHITOSAN; POLYMERIC DRUG CARRIER; GROWTH-FACTOR-BETA; FACTOR-KAPPA-B; PROXIMAL TUBULE; POLY(ESTER AMINE); TARGETED DELIVERY; EPITHELIAL-CELLS; RISK-FACTORS;

D O I：

10.4155/fmc-2020-0335

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Globally, diabetic nephropathy (DN) is the foremost cause of end-stage renal disease. With the incidence of diabetes increasing day by day, DN's occurrence is expected to surge to pandemic proportions. Current available therapeutic interventions associated with DN emphasize blood pressure, glycemia and lipid control while ignoring DN's progression mechanism at a molecular level. This review sheds light on the molecular insights involved in DN to help understand the initiation and progression pattern. Further, we summarize novel strategies with reported applications in developing a nanomedicine-based platform for DN-targeted drug delivery to improve drug efficacy and safety.

引用

页码：663 / 686

页数：24

共 50 条

[1] TREATMENT OF DIABETIC NEPHROPATHY
TUCKER, WR
KARK, RM
MODERN TREATMENT, 1967, 4 (01): : 31 - &
[2] The treatment of diabetic nephropathy
Elgandaoui, S.
DIABETES & METABOLISM, 2007, 33 : S95 - S95
[3] Treatment of diabetic nephropathy with acupuncture
Chu Q.
Wang L.
Liu G.-Z.
Journal of Acupuncture and Tuina Science, 2007, 5 (2) : 103 - 105
[4] Diabetic nephropathy: Prevention and treatment
Parving, HH
Harrington, JT
Lewis, J
Boner, G
Lewis, EJ
Viberti, G
Gilbert, R
Raz, I
Cooper, M
Rossing, K
KIDNEY INTERNATIONAL, 2001, 60 (05) : 2041 - 2055
[5] Diabetic nephropathy - complications and treatment
Lim, Andy K. H.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 : 361 - 381
[6] Atrasentan for the treatment of diabetic nephropathy
Egido, Jesus
Rojas-Rivera, Jorge
Mas, Sebastian
Ruiz-Ortega, Marta
Belen Sanz, Ana
Gonzalez Parra, Emilio
Gomez-Guerrero, Carmen
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (06) : 741 - 750
[7] Treatment options in diabetic nephropathy
Morgenroth, R.
Mertens, Peter R.
Herzog, C.
Scurt, Florian G.
DIABETOLOGIE, 2023, 19 (03): : 271 - 280
[8] Diabetic nephropathy: diagnosis and treatment
Fineberg, Daniel
Jandeleit-Dahm, Karin A. M.
Cooper, Mark E.
NATURE REVIEWS ENDOCRINOLOGY, 2013, 9 (12) : 713 - 723
[9] Adiponectin for the treatment of diabetic nephropathy
Lee, Jun Young
Yang, Jae Won
Han, Byoung Geun
Choi, Seung Ok
Kim, Jae Seok
KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (03): : 480 - 491
[10] The treatment of hypertension in diabetic nephropathy
Lewis, EJ
JOURNAL OF HUMAN HYPERTENSION, 1996, 10 (10) : 675 - 677

← 1 2 3 4 5 →